

Mohammad R. Marzabadi, et al.  
Application No: Not Yet Known  
Filed: Herewith  
Page 3


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listings of the Claims:

Claims 1-39. (cancelled)

Claim 40. (original) A compound having the structure:



wherein each R is independently -H; -F; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C<sub>2</sub>-C<sub>7</sub> alkenyl or alkynyl; -N(R<sub>3</sub>)<sub>2</sub>; -NO<sub>2</sub>; -CN; -CO<sub>2</sub>R<sub>3</sub>; -OR<sub>3</sub>; or -CON(R<sub>3</sub>)<sub>2</sub>;

wherein each R<sub>1</sub> is independently -H; F; Cl; Br; I; -NO<sub>2</sub>; -N<sub>3</sub>; -CN; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C<sub>2</sub>-C<sub>7</sub> alkenyl or alkynyl; C<sub>3</sub>-C<sub>7</sub> cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R<sub>3</sub>)<sub>2</sub>; -OR<sub>3</sub>; -(CH<sub>2</sub>)<sub>p</sub>OR<sub>3</sub>; -COR<sub>3</sub>; -CO<sub>2</sub>R<sub>3</sub>; -CON(R<sub>3</sub>)<sub>2</sub>; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; Cl; Br; I; COR<sub>3</sub>; CO<sub>2</sub>R<sub>3</sub>; -CON(R<sub>3</sub>)<sub>2</sub>; CN; -NO<sub>2</sub>; -N(R<sub>3</sub>)<sub>2</sub>; -OR<sub>3</sub>; -SR<sub>3</sub>; (CH<sub>2</sub>)<sub>q</sub>OR<sub>3</sub>; (CH<sub>2</sub>)<sub>q</sub>SR<sub>3</sub>; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C<sub>2</sub>-C<sub>7</sub> alkenyl,

Mohammad R. Marzabadi, et al.  
Application No: Not Yet Known  
Filed: Herewith  
Page 4

C<sub>2</sub>-C<sub>7</sub> alkynyl; C<sub>3</sub>-C<sub>7</sub> cycloalkyl, monofluorocycloalkyl,  
polyfluorocycloalkyl or cycloalkenyl;

wherein each R<sub>3</sub> is independently -H; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C<sub>2</sub>-C<sub>7</sub> alkenyl or alkynyl; C<sub>3</sub>-C<sub>7</sub> cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

wherein R<sub>5</sub> is -H; -NO<sub>2</sub>; -N<sub>3</sub>; -CN; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C<sub>2</sub>-C<sub>7</sub> alkenyl or alkynyl; C<sub>3</sub>-C<sub>7</sub> cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R<sub>3</sub>)<sub>2</sub>; -OR<sub>3</sub>; -(CH<sub>2</sub>)<sub>p</sub>OR<sub>3</sub>; -COR<sub>3</sub>; -CO<sub>2</sub>R<sub>3</sub>; -CON(R<sub>3</sub>)<sub>2</sub>; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; Cl; Br; I; COR<sub>3</sub>; CO<sub>2</sub>R<sub>3</sub>; -CON(R<sub>3</sub>)<sub>2</sub>; CN; -NO<sub>2</sub>; -N(R<sub>3</sub>)<sub>2</sub>; -OR<sub>3</sub>; -SR<sub>3</sub>; (CH<sub>2</sub>)<sub>q</sub>OR<sub>3</sub>; (CH<sub>2</sub>)<sub>q</sub>SR<sub>3</sub>; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C<sub>2</sub>-C<sub>7</sub> alkenyl, C<sub>2</sub>-C<sub>7</sub> alkynyl; C<sub>3</sub>-C<sub>7</sub> cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

wherein V is H; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR<sub>3</sub>; CO<sub>2</sub>R<sub>3</sub>; -CON(R<sub>3</sub>)<sub>2</sub>; CN; -NO<sub>2</sub>; -N(R<sub>3</sub>)<sub>2</sub>; -OR<sub>3</sub>; -SR<sub>3</sub>; (CH<sub>2</sub>)<sub>q</sub>OR<sub>3</sub>; (CH<sub>2</sub>)<sub>q</sub>SR<sub>3</sub>; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C<sub>2</sub>-C<sub>7</sub> alkenyl, C<sub>2</sub>-C<sub>7</sub> alkynyl; C<sub>3</sub>-C<sub>7</sub> cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

Mohammad R. Marzabadi, et al.  
Application No: Not Yet Known  
Filed: Herewith  
Page 5

wherein W is

(a)  $C_3-C_7$  cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl optionally substituted with one or more  $COR_3$ ;  $CO_2R_3$ ;  $-CON(R_3)_2$ ;  $CN$ ;  $-NO_2$ ;  $-N(R_3)_2$ ;  $-OR_3$ ;  $-SR_3$ ;  $(CH_2)_qOR_3$ ;  $(CH_2)_qSR_3$ ; straight chained or branched  $C_1-C_7$  alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched  $C_2-C_7$  alkenyl,  $C_2-C_7$  alkynyl;  $C_3-C_7$  cycloalkyl; or

(b) aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I;  $COR_3$ ;  $CO_2R_3$ ;  $-CON(R_3)_2$ ;  $CN$ ;  $-NO_2$ ;  $-N(R_3)_2$ ;  $-OR_3$ ;  $-SR_3$ ;  $-(CH_2)_qOR_3$ ;  $-(CH_2)_qSR_3$ ; straight chained or branched  $C_1-C_7$  alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched  $C_2-C_7$  alkenyl,  $C_2-C_7$  alkynyl;  $C_3-C_7$  cycloalkyl;

wherein each m is independently an integer from 0 to 3 inclusive;

wherein n is an integer from 0 to 2 inclusive;

wherein p is an integer from 1 to 7 inclusive;

wherein q is an integer from 1 to 3 inclusive;


wherein t is an integer from 2 to 6 inclusive;

or a pharmaceutically acceptable salt thereof.


Claim 41. (currently amended) A The (+) enantiomer of the compound of claim 40.

Claim 42. (currently amended) A The (-) enantiomer of the compound of claim 40.

Claim 43. (currently amended) The compound of claim 40 having the structure:





Claim 44. (currently amended) The compound of claim 43 having the structure:



Claim 45. (currently amended) A The compound of claim 43 44 wherein W is phenyl optionally substituted with one or more F; Cl; Br; I; COR<sub>3</sub>; CO<sub>2</sub>R<sub>3</sub>; -CON(R<sub>3</sub>)<sub>2</sub>; CN; -NO<sub>2</sub>; -N(R<sub>3</sub>)<sub>2</sub>; -OR<sub>3</sub>; -SR<sub>3</sub>; -(CH<sub>2</sub>)<sub>q</sub>OR<sub>3</sub>; -(CH<sub>2</sub>)<sub>q</sub>SR<sub>3</sub>; or straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl groups.

Claim 46. (currently amended) A The compound of claim 45 having the structure:



Claims 47-81. (cancelled)

Claim 82. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1, ~~34 or 38~~ 40 and a pharmaceutically acceptable carrier.

Claim 83. (original) The pharmaceutical composition of claim 82, wherein the amount of the compound is an amount from about 0.01mg to about 500mg.

Claim 84. (original) The pharmaceutical composition of claim 83, wherein the amount of the compound is an amount from about 0.1mg to about 60mg.

Claim 85. (original) The pharmaceutical composition of claim 84, wherein the amount of the compound is an amount from about 1mg to about 20mg.

Claim 86. (original) The pharmaceutical composition of claim 82, wherein the carrier is a liquid and the composition is a solution.

Claim 87. (original) The pharmaceutical composition of claim 82, wherein the carrier is a solid and the composition is a tablet.

Mohammad R. Marzabadi, et al.  
Application No: Not Yet Known  
Filed: Herewith  
Page 8

Claim 88. (original) The pharmaceutical composition of claim 82, wherein the carrier is a gel and the composition is a suppository.

Claim 89. (currently amended) A pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 1, ~~34 or 38~~ 40 and a pharmaceutically acceptable carrier.

Claim 90. (currently amended) A process for making a pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1, ~~34 or 38~~ 40 and a pharmaceutically acceptable carrier.

Claim 91. (new) A method of treating a subject from suffering from bulimia, obesity or bulimia nervosa which comprises administering to the subject an amount of a compound of claim 40 and a pharmaceutically acceptable salt.

Claim 92. (new) A method of treating a subject from suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of claim 40 and a pharmaceutically acceptable salt.